STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which ...
STOCKHOLM, Sweden, March 21, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401 ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Why BioArctic is on investors’ radar today BioArctic (OM:BIOA B) has recently drawn ...
BioArctic AB reported its third quarter 2025 results, highlighting SEK133.35 million in sales compared to SEK76.63 million a year earlier, alongside a net loss of SEK86.87 million due to increased R&D ...
Stockholm, Sweden, April 29, 2026 - BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the global sales of Leqembi surpassed EUR 500 million in Eisai's fiscal y ...
BioArctic AB, a public Swedish biopharma company, recently announced that they received allowance of a patent application directed to a method of promoting axonal regeneration using a biodegradable ...
Comments from the CEO, '2025 was a record year for BioArctic, with an operating profit of more than SEK 1.2 billion' 2025 was a fantastic year for BioArctic, with record financial results, another ...
STOCKHOLM, April 10, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA-B) (STOCKHOLM: BIOA-B) commitment to its Sustainable Innovation approach - combining scientific progress with responsible ...
STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti ...
BioArctic shares fell about 5% on Tuesday after Goldman Sachs cut the stock to "neutral" from "buy," saying recent gains have narrowed upside to its revised 12-month price target of SEK355, down from ...
STOCKHOLM--(BUSINESS WIRE)--BioArctic announced that it entered into a strategically important collaboration with AbbVie (NYSE: ABBV), a global biopharmaceutical company, to develop and commercialize ...
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi Iqlik was launched for weekly maintenance dosing and Eisai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results